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Abstract
Bacterial superantigens, a diverse family of toxins, induce an inflammatory cytokine storm that can lead to lethal shock.
CD28 is a homodimer expressed on T cells that functions as the principal costimulatory ligand in the immune response
through an interaction with its B7 coligands, yet we show here that to elicit inflammatory cytokine gene expression and
toxicity, superantigens must bind directly into the dimer interface of CD28. Preventing access of the superantigen to CD28
suffices to block its lethality. Mice were protected from lethal superantigen challenge by short peptide mimetics of the
CD28 dimer interface and by peptides selected to compete with the superantigen for its binding site in CD28.
Superantigens use a conserved b-strand/hinge/a-helix domain of hitherto unknown function to engage CD28. Mutation of
this superantigen domain abolished inflammatory cytokine gene induction and lethality. Structural analysis showed that
when a superantigen binds to the T cell receptor on the T cell and major histocompatibility class II molecule on the antigen-
presenting cell, CD28 can be accommodated readily as third superantigen receptor in the quaternary complex, with the
CD28 dimer interface oriented towards the b-strand/hinge/a-helix domain in the superantigen. Our findings identify the
CD28 homodimer interface as a critical receptor target for superantigens. The novel role of CD28 as receptor for a class of
microbial pathogens, the superantigen toxins, broadens the scope of pathogen recognition mechanisms.
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Introduction
As the principal costimulatory receptor, CD28 is a critical
regulator of the immune response [1–3]. Expressed constitutively
on T cells, CD28 is a homodimer that interacts with its B7
coligands to transduce the signal essential for an immediate T cell
response [2–5]. B7-2 is expressed constitutively and induced
immediately, whereas B7-1 is expressed only later [5,6]; hence,
interaction of B7-2 with CD28 regulates signaling by antigens
early in the immune response [7,8]. Apart from its B7 coreceptors,
CD28 has no other known ligands.
Bacterial superantigens are a family of proteins secreted by
Staphylococcus aureus and Streptococcus pyogenes that induce toxic shock
by activating an immune response, orders of magnitude higher in
intensity than that elicited by regular antigens. Bypassing restricted
presentation of conventional antigens which typically activate
,0.01% of T cells, superantigens bind directly as intact proteins to
most major histocompatibility class II (MHC-II) and T cell
receptor (TCR) molecules, activating up to 20% of T cells [9–11].
This results in massive induction of the T helper 1 (Th1) cytokines
interleukin-2 (IL2), interferon-c (IFN-c), and tumor necrosis factor
(TNF) that mediate toxic shock. Nevertheless, superantigen action
also requires CD28 costimulation [12–14].
Induction of human T helper 1 (Th1) cytokine gene expression
by divergent superantigens is inhibited by a dodecamer peptide
that protects mice from their lethal effect [15]. The peptide shows
homology to the b-strand(8)/hinge/a-helix(4) domain in staphy-
lococcal enterotoxin (SE) B, structurally conserved in superanti-
gens yet remote from MHC-II and TCR binding sites. Because
this domain is essential for superantigen action [15], we considered
that it may engage a third receptor. We show here that this
receptor is CD28. This costimulatory molecule is co-opted by
superantigens as receptor. Superantigens must bind directly into
the homodimer interface of CD28 to elicit toxicity. Blocking access
of a superantigen to CD28 is sufficient to block lethal toxic shock.
Peptide mimetics of the CD28 dimer interface inhibited the
induction of Th1 cytokines and protected mice from lethal
superantigen exposure. These experiments identify the CD28
homodimer interface as a receptor target for superantigen toxins
and reveal a novel role for CD28 in pathogen recognition.
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Superantigen Mimetic Peptide Inhibits SEB Action and
CD28 Signaling
Induction of cytokine genes in human PBMC by superantigens
and their lethality in mice is blocked by YNKKKATVQELD
(p12A), a peptide variant of SEB150–161, TNKKKVTAQELD, the
b-strand(8)/hinge/a-helix(4) domain that is conserved among
divergent superantigens [15]. The more stable peptide
VQYNKKKATVQELD (p12B) carrying VQ from SEB148–149
inhibited SEB-mediated induction of IL2, IFN-c, and TNF-a
mRNA and protein (Figure 1A) but not induction of Th2-type
cytokines IL4 and IL10 (Figure 1B). Thus, the balance of cytokines
induced by SEB was shifted towards the Th2 type, which can
explain why mice protected from lethal superantigen challenge by
YNKKKATVQELD swiftly acquired immunity against further
challenges and developed broadly protective immunoglobulins
[15,16].
Mimetic peptide p12B acts early during the immediate reponse
to the superantigen, blocking mRNA induction within hours, with
inhibition evident already by 2 h (Figure 1A), showing the
sensitivity of the mRNA determination. Protein levels reflect this
inhibition at the later times, by 6–8 h. These results demonstrate
an inhibition of de novo gene induction.
Binding sites in SEB for TCR and MHC-II are remote from the
b-strand(8)/hinge/a-helix(4) domain (Figure 1C). We postulated
that Th1 cytokine induction requires an additional receptor and
that a superantigen binds this receptor via its accessible b-
strand(8)/hinge/a-helix(4) domain, rendering this binding sensi-
tive to competition by peptide mimetics.
CD28-deficient mice are resistant to superantigen toxicity and
this was explained by the need for B7/CD28 costimulation
[13,14]. SEB-mediated induction of IL2 and IFN-c genes in
human PBMC was inhibited by aB7-2 but not by aB7-1
monoclonal antibody (mAb); by contrast, induction of IL4 and
IL10 was resistant (Figure S1A). Moreover, IL2 and IFN-c mRNA
induction by SEB was inhibited selectively by soluble CD28
comprising its extracellular domain fused to IgG1-Fc dimer
(CD28-Fc) (Figure S1B). Although CD28-Fc could inhibit SEB
action by competing for B7-2, we considered that it might compete
with cell-surface CD28 for SEB. Because induction of Th1 but not
Th2 cytokines relies on B7-2/CD28 signaling and is selectively
inhibited by p12B, we hypothesized that superantigens use CD28
as receptor.
To study the role of CD28 directly, we induced IL2 and IFN-
c mRNA with an activating mAb, aCD28. This induction was
blocked by p12B (Figure 1D). aCD28 failed to bind p12B,
suggesting that p12B competes with aCD28 in binding to cell-
surface CD28. IL2, IFN-c,a n dTNF-a gene induction by aCD3
was resistant to p12B (Figure 1E), showing that p12B does not
block signaling through the TCR. By contrast, induction of
Th1 cytokine gene expression by aCD3 jointly with aCD28, a
model for the normal immune response [17], was severely
inhibited by p12B ( F i g u r e1 F ) .T h u s ,t h ep e p t i d eb l o c k saT h 1
cytokine response transduced through CD28. p12B did not
inhibit IL10 induction, implying that it leaves signaling through
the TCR intact. aCD28 failed to induce IL10 or to enhance its
induction by aCD3. These results show that as in dendritic cells
[18], IL10 induction in PBMC is independent of CD28. This
explains the observed resistance of SEB-mediated IL10
induction to p12B, aB7-2, and CD28-Fc. Because a peptide
mimetic of the b-strand(8)/hinge/a-helix(4) domain blocked
CD28-mediated Th1 cytokine induction even in the absence of
SEB, we considered that superantigens may engage CD28
through this domain.
Functional Interaction between Superantigen and CD28
To obtain evidence for a direct, functional interaction between
superantigen and CD28, we repeatedly panned a random 12-mer
phage-display library on immobilized CD28-Fc, displacing bound
phages with SEB. We sequenced 36 peptides and analyzed three
for SEB antagonist activity. Phage display peptides pe12
(SHFTHNRHGHST) and pc3 (FHKHKNPGSPII) but not the
related pc9 (FHKHNYKSPPII) inhibited IL2 and IFN-c mRNA
induction by SEB but not induction of IL10, shown for pe12
(Figure 2A). In about equimolar ratio to SEB, pe12 and pc3
protected 8/10 and 7/10 mice from lethal challenge that left no
survivors in the control group. Thus, superantigen antagonists
effective in vivo were selected from random peptide sequences
solely by affinity for the SEB binding site in CD28.
SEB Binds to Cell-Surface CD28
We next expressed human CD28 having GFP fused C-
terminally to its intracellular domain in transfected cells
(Figure 2B). SEB bound to the surface of cells that expressed
CD28 but not to cells in the same field that failed to express CD28.
Independently, expression of natural human CD28 and binding of
SEB colocalized to the cell surface (Figure 2C). Binding of anti-
CD28 Ab to CD28-expressing cells blocked subsequent binding of
labeled SEB (Figure 2D). Thus, SEB binds to cell-surface CD28
even in the absence of MHC-II or TCR.
SEB Uses Its b-strand(8)/hinge/a-helix(4) Domain to Bind
CD28
SEB bound CD28-Fc directly in far-western analysis whereas
lysozyme did not (Figure 2E), showing that binding of SEB to
CD28 will survive denaturation and is robust. Using surface
plasmon resonance (SPR), we detected binding of purified CD28-
Fc but not of human IgG to immobilized SEB (Figures 3A, S2A
and S2B).
Author Summary
Induction of protective immunity involves the expression
of inflammatory cytokines, proteins that mediate and
respond to immune signals. However, excessive cytokine
induction can lead to disease, including, at very high levels,
lethal toxic shock. Staphylococcal and streptococcal
superantigens are a broad family of bacterial protein
toxins that induce such a lethal cytokine storm, orders of
magnitude higher in intensity than that elicited during
normal immune responses. A key participant in every
immune response is the costimulatory receptor CD28,
which forms a protein dimer to mediate the immune
response. Hitherto, CD28 was not known to bind microbial
components. Here, we show that superantigens co-opt
CD28 as their receptor and that to induce a cytokine storm,
superantigens must bind directly into the dimer interface
of CD28. The interaction between CD28 and the bacterial
superantigen can be blocked with peptides—short protein
fragments that mimic the contact domains in the intact
superantigen or in CD28. These peptides attenuate
inflammatory cytokine gene induction and thus protect
animals from lethal toxic shock. Our finding that CD28 is a
receptor for the superantigen toxins broadens the scope
of microbial pathogen recognition mechanisms and
provides a novel approach for designing therapeutics that
protect against toxic shock.
Superantigens Signal through CD28 Dimer Interface
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peptide p12C (YNKKKATVQELD abutted by Cys at both
termini) which was as active as p12A (YNKKKATVQELD
abutted by D-Ala at both termini) in inhibiting SEB-mediated IL2
and IFN-c mRNA induction (Figure S3). CD28-Fc bound p12C
directly (Figure 3B) and specifically, as no binding was detected for
IgG or ubiquitin (Figure S2C and S2D). SEB competitively
inhibited binding of CD28-Fc to immobilized p12C (Figure 3C).
The signal of CD28-Fc binding declined progressively with
increasing SEB concentration showing that SEB did not bind to
the immobilized peptide. Half-maximal inhibition occurred when
SEB was in 1.5-fold excess over CD28-Fc. The finding that SEB
free in solution inhibited binding of CD28 free in solution to
immobilized superantigen mimetic peptide implies that the two
proteins bind each other in solution, independent of any surface
consideration and provides direct evidence that SEB uses its b-
strand(8)/hinge/a-helix(4) domain to bind CD28. This competi-
tion analysis yielded KD=2.3 mM for complex formation between
free SEB and CD28-Fc. Thus, SEB binds CD28 with similar
affinity as TCR and MHC-II [19,20]. By contrast, soluble
costimulatory receptor Programmed Death-1 (PD-1) failed to
bind SEB (Figure 3D).
Binding of CD28 to the peptide was sensitive to mutations.
Random scrambling of p12C abrogated CD28 binding (Figure 3E).
CD28-Fc bound significantly better to p12C than to its natural
homolog pSEB (Figure 3F); pSEB is far weaker as SEB antagonist
[15], showing a correlation between the ability of the peptide to
bind CD28 and its biological activity as superantigen antagonist. A
single alanine substitution in pSEB (pSEBK) reduced binding by
.50% (Figure 3F). A similar substitution in p12C (p12K) severely
reduced binding; pairwise substitutions abolished it (p12YK,
p12KD) (Figure 3G–I). The mutations and scrambling created
negative control surface, showing specificity of the binding. Thus,
SEB binds CD28 directly through its b-strand(8)/hinge/a-helix(4)
domain, explaining the inhibitory effect of mimetic p12B on SEB-
induced and CD28-mediated Th1 cytokine gene expression.
CD28 Uses Its Homodimer Interface to Bind SEB
Since p12C bound CD28, the observation that p12B blocked
signaling by aCD28 suggested that p12B competes with aCD28
for its epitope in CD28. Epitope mapping of aCD28 defined
CD28116–124, HVKGKHLCP; HVKGKH aligns with YVIDPE
in CTLA-4 (Figure 4A) [1]. CD28 and CTLA-4 are homologous
and fold similarly [21] yet their sequences differ in this domain and
in residues 10–15, likely to prevent heterodimer formation [1,5].
In the folded CTLA-4 protein, these two domains are juxtaposed,
creating the dimer interface. The conserved B7 binding domain
MYPPPY is located on the opposite side. Peptide HVKGKHLCP
(p1TA) abrogated induction of IFN-c mRNA by aCD28
(Figure 4B), functional evidence that aCD28 indeed engages
CD28116–124, part of the putative CD28 dimer interface [21].
p1TA inhibited cytokine gene induction by SEB (Figure 4C and
4D), implying that to elicit a Th1 response, SEB must bind CD28
at a site overlapping with HVKGKHLCP.
We next synthesized SPMLVAYD (p2TA; CD288–15), a
mimetic of the second CD28 dimer interface domain predicted
from alignment with CTLA-4 (Figure 4A). In the available
structure for CD28, p2TA overlaps with the dimer interface; most
of the flexible p1TA domain was not resolved [21]. Like p1TA,
p2TA antagonized SEB-mediated induction of Th1 cytokine genes
(Figure 4C and 4E). The p1TA/p2TA combination was not more
potent (Figure 4C). These results provide strong evidence that the
functional superantigen binding site in CD28 is composite and
includes dimer interface residues in p1TA and p2TA.
SEB engages only the MHC-II a-chain whereas SEA binds also
the b-chain, increasing its affinity for MHC-II over 10-fold [22–
24]. SEA was as sensitive as SEB to p1TA and p2TA (Figure 4F).
Thus, interaction with the CD28 dimer interface is used generally
by superantigens and not merely to compensate for weak binding
of SEB to MHC-II. Even though the superantigen toxic shock
syndrome toxin-1 (TSST-1) is only 6% homologous with SEB and
binds the TCR via a different domain [25], the b-strand(8)/hinge/
a-helix(4) domains in TSST-1 and SEB show spatial conservation
[15]. Indeed, p1TA and p2TA also inhibited IL2 and IFN-c
mRNA induction by TSST-1 (Figure 4G).
p1TA and p2TA blocked superantigen lethality. Whereas no
controls (0/10) survived SEB challenge, 7/10 mice survived that
received p1TA shortly before SEB exposure (Figure 5A). p1TA was
protective when present in 3.6-fold excess over SEB. Moreover, in
only 0.8-fold ratio to SEB, p2TA protected 8/10 mice from lethal
shock. Scrambling p1TA sequence abolished its ability to block
IFN-c mRNA induction by SEB. Randomly scrambled peptides
p1TAsc and p2TAsc failed to provide significant protection of mice
from the lethal effect of SEB, showing specificity for p1TA and
p2TA.p 12B in 12-fold excess over SEB gave comparable
protection. We conclude that the CD28 dimer interface plays a
critical role in mediating the deleterious response to a superan-
tigen.
To validate the concept that the superantigen binding site in
CD28 is the dimer interface, we next examined whether p1TA and
p2TA bind superantigens directly. To overcome limitations of SPR
affinity measurement using divalent ligands, we analyzed binding
of SEB to immobilized CD28-Fc (Figure 5B) which yielded
KD=2.3 mM under conditions where the highest analyte
concentrations approached 10-fold the KD, allowing for an
accurate estimation; this KD agrees well with that derived from
competition analysis (Figure 3C). Immobilized CD28-Fc readily
bound B7-2-Fc (Figure S2E) but not ribonuclease (Figure 5B), a
control protein similar in size to SEB, supporting specificity of SEB
binding. SEB bound to immobilized p1TA and p2TA (Figure 5C
and 5D), with KD values in the micromolar range (Table S1).
Binding to p2TAsc was severely impaired (Figure 5E), showing
specificity for the natural CD28 sequence. Likewise, SEA bound
p1TA and p2TA (Figure 5F and 5G). Short peptide mimetics of the
CD28 dimer interface, p1TA and p2TA, bind superantigens
Figure 1. Superantigen mimetic peptide blocks SEB action and CD28 signaling. (A, B) p12B (10 mg/ml) inhibits SEB-mediated induction in
human PBMC of IL2, IFN-c, and TNF-a mRNA (autoradiograms) and of protein (graphs; data are shown as means 6 SEM (n=3 experiments)) (A) but
not of IL4 and IL10 (B). mRNA was quantitated by RNase protection analysis; b-actin mRNA indicates equal loading of RNA. (C) In SEB structure
(pdb3seb.ent), amino acid residues in the 150–161 b-strand(8)/hinge/a-helix(4) domain are shown in purple, with solvent-accessible residues [36]
N151, K153, and K154 in orange. Residues contacting MHC-II are colored red; those contacting the TCR are colored green [37]. (D) p12B inhibits
induction of IL2 and IFN-c mRNA in PBMC by aCD28 mAb. PBMC were induced by aCD28 (2.5 mg/ml) alone or with 10 mg/ml p12B. To show that
aCD28 does not bind p12B,p 12B and CD28-Fc were immobilized and binding of mouse aCD28 was assayed. (E) p12B fails to inhibit induction of IL2,
IFN-c, and TNF-a genes by aCD3. PBMC were incubated with aCD3 (0.1 mg/ml) alone or with 10 mg/ml p12B. mRNA and secreted cytokines were
quantitated. (F) p12B inhibits aCD28/aCD3-mediated induction of IL2, IFN-c, and TNF-a genes but not of IL10. PBMC were incubated with aCD3,
aCD28, or both, with or without 10 mg/ml p12B. mRNA and secreted cytokines were determined.
doi:10.1371/journal.pbio.1001149.g001
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PLoS Biology | www.plosbiology.org 4 September 2011 | Volume 9 | Issue 9 | e1001149Figure 2. SEB binds to CD28. (A) Phage display peptides selected by affinity for the SEB binding site in CD28 are SEB antagonists that protect mice
from killing by SEB. PBMC were induced with SEB alone or with 0.1 mg/ml pc3,p e12,o rp c9, a negative control. IL2 and IFN-c mRNA are shown; b-actin
mRNA indicates equal loading of RNA. For pe12, IL10 was determined (data are shown as means 6 SEM (n=3 experiments)). Mice (n=10 per group)
were challenged with 6 mg SEB alone or with 0.2 mgp e12 or 0.5 mgp c3; p for survival, 10
24. (B–D) Binding of SEB to cell surface CD28. Representative
fields of confocal microscopy are shown. In (B), HEK293-T cells were transfected to express CD28-GFP fusion protein (green) and after 48 h incubated
for 1 h with Alexa-Fluor-633-labeled SEB (red). In (C), BHK-21 hamster cells were transfected with CD28 cDNA vector and after 48 h incubated
successively for 30 min with labeled SEB (red), goat polyclonal aCD28, and Cy2-labeled donkey anti-goat IgG (green). In (D), BHK-21 cells were
transfected to express CD28 and after 48 h incubated first with goat polyclonal aCD28 and Cy2-labeled donkey anti-goat IgG (top) and only then with
labeled SEB (bottom). (E) Binding of SEB to CD28. SEB, lysozyme, and polyclonal aCD28 (Ab) were separated on duplicate SDS-PAGE gels. Coomassie
blue staining (top); far-western blot with CD28-Fc (bottom); M, size marker.
doi:10.1371/journal.pbio.1001149.g002
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PLoS Biology | www.plosbiology.org 5 September 2011 | Volume 9 | Issue 9 | e1001149Figure 3. SEB binds CD28 through its b-strand(8)/hinge/a-helix(4) domain. (A and B) Binding of CD28-Fc in 2-fold increments from 0.25 mM
to immobilized SEB (A) and from 0.125 mMt op 12C (B). (C) Binding of CD28-Fc (2 mM) to p12C without SEB (top curve) or with SEB in 2-fold increments
from 0.78 mM (6 lower curves, top to bottom). (D) Binding of 2 mM PD1-Fc and CD28-Fc to immobilized SEB. (E) Binding of CD28-Fc in 2-fold
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activity, apparently because they compete with cell-surface
CD28 for the b-strand(8)/hinge/a-helix(4) domain in the
superantigen.
We used western blotting to show that p1TA,p 2TA, and p12A
but not scrambled p12Asc block binding of SEB to cells expressing
CD28 (Figure 5H). SEB binding was abrogated by aCD28 but
insensitive to anti-B7-2 Ab. Thus, two classes of peptides block the
interaction between superantigen and CD28: mimetics of the
CD28 homodimer interface and of the b-strand(8)/hinge/a-
helix(4) domain in superantigens.
CD28 peptides p3TA,p 4TA, and p5TA harbor additional
contact residues in the crystallographic dimer interface of CD28
(Figure 4A). These mimetic peptides inhibited IFN-c and TNF-a
induction to the same extent as p1TA and p2TA but had no effect
on IL10 induction (Figure 5I). Thus, each of five peptides covering
distinct portions of the CD28 dimer interface (Movie S1, Figure
S4) is a superantigen antagonist.
SEB induced a transient change in surface accessibility of
epitope HVKGKHLCP at the CD28 homodimer interface (Figure
S5). The epitope was not detected by aCD28 at 0 and 24 h,
showing that it is shielded in the dimer, but became accessible 6 h
after exposure to SEB. Most plausibly, by opening the dimer
interface and engaging one CD28 monomer, SEB renders the
second monomer accessible to aCD28.
Toxicity of SEB Is Abrogated by Mutation of Its CD28-
Binding Domain
Experiments with peptides capable of blocking Th1 cytokine
induction in human PBMC and lethal shock in mice show that
SEB must bind CD28 to exert its toxicity. We next mutated the b-
strand(8)/hinge/a-helix(4) domain in holo-SEB. SEB
T150A/K152A
(tk2) carries alanine substitutions in two highly conserved residues
[15] critical for binding of CD28 in peptide context (Figure 3G
and 3H) and adjacent to solvent-exposed residues (Figure 1C). The
tk2 mutation severely impaired the ability of SEB to induce IL2,
IFN-c, and TNF-a mRNA and protein yet left induction of IL10
unabated (Figure 6A), evidence that the ability to signal through
MHC-II and TCR remained fully intact, an essential control
showing that the protein was not denatured by the mutation. The
tk2 mutation abolished the lethality of SEB. No mice (0/5)
survived challenge with wild type (wt) SEB yet all (5/5) survived
challenge with tk2 (Figure 6B). Thus, an intact b-strand(8)/hinge/
a-helix(4) domain is essential for SEB toxicity.
The tk2 mutation enhanced binding of SEB to CD28-Fc,
maximal response increasing 3-fold (Figure 6C); whereas wt SEB
again yielded a KD in the micromolar range, for tk2 the affinity
reached nanomolar values (Table S2). This result was unexpected
given the loss of lethality of tk2 and lack of affinity of p12YK for
CD28-Fc. Enhanced binding of tk2 did not result from interaction
with a different site in CD28, as it was accompanied by increased
binding to both p1TA and p2TA. Loss of the lethality of tk2 and of
its ability to induce Th1 cytokines shows that the interaction of tk2
with CD28 is nonproductive. We considered that the higher
affinity of tk2 for CD28 might render it dominant-negative.
Indeed, even when present at a 10-fold lower concentration, tk2
significantly reduced the induction of IL2, IFN-c, and TNF-a by
wt SEB (Figure 6D). Yet tk2 induced IL10 additively with wt SEB,
confirming the selectivity of the dominant-negative phenotype.
The tk2 mutation, which affects affinity for CD28 but not signaling
through MHC-II/TCR, shows that direct engagement of CD28
by the superantigen via its b-strand(8)/hinge/a-helix(4) domain is
critical for a deleterious Th1 cytokine response. To elicit
productive signaling for Th1 cytokine gene induction and lethality,
the superantigen must bind CD28 with moderate affinity.
Structural analysis shows that a superantigen can bind
simultaneously to CD28 and the TCR on the T cell and MHC-
II on the antigen-presenting cell (Figure 7). CD28 can be
accommodated readily as third superantigen receptor in the
quaternary complex, with the CD28 dimer interface oriented
towards the b-strand/hinge/a-helix domain in the superantigen.
Discussion
These experiments identify the CD28 dimer interface as a
receptor target for superantigens. We show that to deliver the
signal for Th1 cytokine induction, a superantigen must co-opt
CD28 as third receptor, in addition to its full reliance on
costimulatory signaling through B7-2/CD28. Thus, superantigens
make unconventional use not only of MHC-II and TCR through
direct binding but also of CD28. Independent lines of evidence
show that the binding site for superantigens in CD28 is the
crystallographic homodimer interface. The superantigen domain
that engages CD28 contains the conserved b-strand/hinge/a-helix
motif [15], remote from MHC-II and TCR binding sites, leaving it
accessible to CD28 (Figure 7). Blocking access of a superantigen to
CD28 is sufficient to block lethal toxic shock. Mice were protected
from lethal SEB challenge by peptide mimetics of the CD28 dimer
interface and of the b-strand/hinge/a-helix domain in superan-
tigens, as well as by random peptides selected to compete with SEB
for its binding site in CD28. The finding that CD28 is a direct
sensor of a class of microbial pathogens, superantigen toxins,
broadens the scope of pathogen recognition mechanisms.
Independent lines of evidence support direct binding of
superantigen to CD28. SEB bound to cell-surface CD28 even in
the absence of MHC-II or TCR. Novel peptide antagonists of
SEB, protective against lethal toxic shock, were selected by phage
display solely for their affinity for the SEB binding site in CD28.
Surface plasmon resonance showed that CD28 binds directly to
SEB, whether one or the other was immobilized and even when
both were free in solution, and specifically to peptide mimetics of
the SEB b-strand(8)/hinge/a-helix(4) domain but not, or poorly,
to mutant peptides in which 1–2 amino acids were changed to
alanine. Conversely, another mutation in such a mimetic peptide,
leading to higher SEB antagonist activity [15], enhanced its
affinity for CD28. This peptide blocked binding of SEB to cell-
surface CD28. Thus, SEB uses its b-strand(8)/hinge/a-helix(4)
domain to bind CD28.
We provide evidence that the superantigen binding site in
CD28 is the dimer interface. CD28 mimetic peptides p1TA and
p2TA corresponding to dimer interface sequences each inhibited
Th1 cytokine gene induction by superantigens as widely different
as SEB, SEA, and TSST-1 and protected mice from lethal SEB
challenge even when present in about equimolar ratio to toxin.
p1TA and p2TA directly bound SEB as well as SEA, with affinities
close to that of CD28. The antagonist activity of these peptides is
explained by their ability to compete with cell-surface CD28 for
superantigen. p1TA and p2TA each blocked binding of SEB to
increments from 0.125 mM to scrambled p12Csc (EKAKYTQLVKDN). (F–I) Mutations in SEB b-strand(8)/hinge/a-helix(4) domain peptides reduce
binding of 2 mM CD28-Fc. SPR responses are compared for immobilized p12C and pSEB (TNKKKVTAQELD), pSEBK (TNAKKVTAQELD) (F), p12K
(YNAKKATVQELD) (G), p12YK (ANAKKATVQELD) (H), and p12KD (YNAKKATVQELA) (I). Representative SPR responses are shown.
doi:10.1371/journal.pbio.1001149.g003
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PLoS Biology | www.plosbiology.org 7 September 2011 | Volume 9 | Issue 9 | e1001149Figure 4. Peptide mimetics of the CD28 dimer interface are superantigen antagonists. (A) CTLA-4/B7-2 complex (1I85.pdb; [1]) and the
dimer interface in CTLA-4. B7-2 is shown in purple and CTLA-4 in blue, with MYPPPY in yellow, YVIDPE (HVKGKH in CD28) in red, and VVLASS
(MLVAYD in CD28) in green, as in the sequence alignment of the extracellular domains of human CD28 and CTLA-4. Amino acids at the
crystallographic dimer interface of CD28 [21] are shown in blue. Positions of peptides are underlined. (B) p1TA antagonizes induction of IFN-c mRNA
by aCD28. PBMC were induced by aCD28 (2.5 mg/ml) alone or with 10 mg/ml of CD28-Fc or p1TA. IFN-c and b-actin mRNA was determined. (C–E)
CD28 dimer interface peptides p1TA and p2TA (0.1 mg/ml) inhibit induction by SEB of IL2 and IFN-c mRNA (C) and IL2, IFN-c, and TNF-a (D and E) in
PBMC (data are shown as means 6 SEM (n=3 experiments)). (F and G) Induction of IL2 and IFN-c mRNA by SEA (F) and TSST-1 (G) alone or with 0.1 (F)
or 10 mg/ml peptide (G); b-actin mRNA indicates equal loading of RNA.
doi:10.1371/journal.pbio.1001149.g004
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PLoS Biology | www.plosbiology.org 8 September 2011 | Volume 9 | Issue 9 | e1001149cell-surface CD28. Each of five peptides overlapping distinct
portions of the CD28 dimer interface was a superantigen
antagonist. We did not perform mutagenesis of the CD28 dimer
interface because mutations therein abrogate cell surface expres-
sion of the CD28 receptor [21], rendering interpretation
problematic.
The CD28 dimer interface has no known role in costimulation
and is remote from the B7 binding site. SEB induces vigorous
expression of Th1 and Th2 cytokines but only the Th1 response,
here defined by induction of IL2, IFN-c,a n dTNF-a genes,
depends on CD28 engagement. By attenuating this response,
antagonist peptides will reduce the synergy between these
cytokines, to allow survival. Our data support the interpretation
that the early Th2 cytokine response induced by a superantigen,
as opposed to Th2 cell differentiation [26], is independent of
CD28 signaling and hence resistant to blocking by the mimetic
peptides. It is tempting to link the selective need for CD28
signaling in the superantigen-mediated induction of IL2, IFN-c,
and TNF-a genes, but not of IL4 and IL10 genes, to the distinct
transcription factor dependence for expression of Th1- versus
Th2-type cytokine genes, involving, respectively, T-bet [27,28]
and GATA-3 [29].
CD28 monomers do not dimerize at low concentrations,
indicating weak noncovalent interaction [21], facilitating displace-
ment by superantigen. Engagement of a superantigen should
displace contacts between the CD28 monomers which are linked
through a disulfide bond [21] beyond the HVKGKH motif in the
dimer interface. This epitope, buried in resting T cells, was
rendered accessible upon exposure to SEB. Our data support the
interpretation that the superantigen induces conformational
change in CD28 that activates signaling, without interfering with
B7-2/CD28 costimulation. More commonly, ligand binding
induces receptor homodimerization needed for signaling, as for
human growth hormone receptor [30] and erythropoietin receptor
[31]. In contrast, the superantigen-binding domain of CD28
overlaps with its homodimer interface.
Figure 5. CD28 dimer interface mimetic peptides bind and antagonize superantigens and protect mice from lethal challenge. (A)
Mice (n=10 per group) were challenged with 6 mg SEB alone or with 1 mgp 1TA,5mgp 12B,o r1mg scrambled peptide p1TAsc (CHGHLVPKK), or with
0.2 mgp 2TA or p2TAsc (ASMDYPVL); controls without SEB received 25 mg peptide; p for survival, 2610
28 (p1TA), 0.38 (p1TAsc), 3610
26 (p2TA), and
0.19 (p2TAsc). PBMC were induced with SEB alone or with 1 mg/ml p1TA or p1TAsc; IFN-c and b-actin mRNA was determined. (B–G) Representative SPR
responses for binding of SEB to immobilized CD28-Fc, p1TA, and p2TA (B–D), of SEB to p2TAsc or p2TA (E) and of SEA to p1TA and p2TA (F and G).
Graphical fits to the binding curves are presented in red color; kinetic parameters show the specificity of these interactions (Table S1). Analyte
concentrations increased in 2-fold increments from 0.156 (C and F), 0.312 (G), 1.56 (B), and 3.12 mM (D); in (E), binding of p2TA and p2TAsc is shown for
the highest of 5 concentrations tested, 10 mM. In (B), curves in blue color show binding of ribonuclease A in four 2-fold increments from 3.12 mMt o
immobilized CD28-Fc. (H) Peptide mimetics of the CD28 dimer interface and of the b-strand(8)/hinge/a-helix(4) domain in SEB inhibit binding of SEB
to cell-surface CD28. 293-T cells were transfected to express CD28 and after 36 h incubated for 1 h without addition (CD28) or with 0.1 mg/ml aCD28,
anti-B7-2 or 10 mg/ml p1TA,p 2TA,p 12A, or its scrambled form p12Asc (EKAKYTQLVKDN), before further incubation for 1 h with 15 mg/ml wt SEB. Cells
were washed 3 times with cold phosphate-buffered saline before lysis. Western blot of equal amounts of total cell protein (Bradford assay) with aSEB
mAb and horseradish peroxidase-conjugated goat anti-mouse IgG shown is from a representative experiment. Bar graph shows intensity of bands for
three independent experiments 6 SD. U, untransfected; EV, empty vector. (I) IFN-c, TNF-a, and IL10 (data are shown as means 6 SEM (n=3)) in
medium from PBMC induced with SEB alone or with 0.1 mg/ml p3TA,p 4TA,o rp 5TA.
doi:10.1371/journal.pbio.1001149.g005
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PLoS Biology | www.plosbiology.org 9 September 2011 | Volume 9 | Issue 9 | e1001149Figure 6. Mutation of SEB b-strand(8)/hinge/a-helix(4) domain affects binding to CD28, Th1 cytokine gene induction and lethality.
(A) Induction of cytokine genes by wt and tk2 mutant SEB. PBMC were induced with 1 ng/ml wt or tk2 SEB; mRNA (autoradiograms) and secreted
cytokines (graphs; data are shown as means 6 SEM (n=3)) are depicted. (B) Lack of lethality of tk2 SEB. Mice (n=5 per group) were challenged with
10 mg wt or tk2 SEB; p for survival, 10
25. (C) Affinity of tk2 SEB for CD28. Representative SPR responses for binding of wt and tk2 SEB to immobilized
CD28-Fc, p1TA, and p2TA are shown for 5 mM wt and tk2 SEB or RNase A to facilitate comparison; kinetic data were collected for five 2-fold increments
in protein concentration from 1.25 mM (Table S2). (D) Dominant-negative phenotype of tk2 SEB. PBMC were induced with 1 ng/ml wt SEB, 0.1 ng/ml
tk2 SEB, or both; secreted cytokines were determined as shown (data are shown as means 6 SEM (n=3)).
doi:10.1371/journal.pbio.1001149.g006
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PLoS Biology | www.plosbiology.org 10 September 2011 | Volume 9 | Issue 9 | e1001149In our mouse model, an accepted model for the lethality of
superantigens [15], most if not all of the mice died within 48 h
after a single exposure to SEB but they were protected by peptides.
By contrast, HLA DR3 transgenic mice were far less sensitive to
SEB challenge, requiring two toxin exposures 48 h apart before
death was induced, and no protection by a b-strand(8)/hinge/a-
helix(4) superantigen domain mimetic peptide was observed
thereafter [32]. The rapid kinetics of toxin action in our mouse
model reflects the rapid course of toxic shock, which was blocked
by the peptides despite their limited halflife. In human PBMC,
induction of Th1 cytokine gene expression, the immediate
response occurring during the first hours after superantigen
exposure, was sensitive to peptides. Binding of SEB to PBMC
proved insensitive to b-strand(8)/hinge/a-helix(4) domain mimetic
peptide [32] as expected, because SEB will also bind to the MHC-
II and TCR, which unlike CD28 are not targeted by this peptide.
The phenotype of tk2 mutant SEB shows that superantigen
activity not only requires binding of CD28 via the b-strand(8)/
hinge/a-helix(4) domain but that this binding must be with
moderate affinity. The mutation led to significantly higher affinity
for CD28 but this binding was nonproductive, as reflected by the
complete loss of lethality of SEB. Mutations in a holoprotein can
change protein conformation and thereby affect ligand binding
properties. However, conformational changes in an intact protein
are not necessarily reflected in short peptides derived from a
limited domain; thus, in peptide p12YK, the same mutation led to
loss of affinity for CD28. Given the similarly moderate affinity of
SEB for CD28, TCR, and MHC-II, we propose that it is the
concerted interaction of the superantigen with all three receptors
that allows for stable synapse formation resulting in exceptionally
strong Th1 cytokine induction and lethality. This affinity
limitation will render superantigen action sensitive to regulation
and allow peptide mimetics that interfere with binding of
superantigen to CD28 to disrupt synapse formation, thus
preventing toxic shock. Two classes of peptides block the
interaction between superantigen and CD28: b-strand/hinge/a-
Figure 7. Model for superantigen action through binding to CD28. Structural model for Th1 cell activation by superantigens through
simultaneous binding to CD28, MHC-II, and TCR. SEC3 (cyan), a close relative of SEB, in complex with TCR Vb (green) and MHC-II (red) extracellular
domains (1jck.pdb; [38]). The SEC3 b-strand/hinge/a-helix domain in magenta is freely accessible to the N-terminal 118-residue portion of the CD28
extracellular domain (1yjd.pdb; [21]). CD28 homodimer interface peptides (Figure 4A) are shown: p1TA (HVK resolved in 1yjd.pdb is red), p2TA (green),
p3TA (pink), p4TA (grey), and p5TA (SNGTII is blue); MYPPPY is yellow. CD28 and TCR are oriented such that their trans-membrane domains (not
shown) can enter the T cell at top; the MHC-II is oriented towards the antigen-presenting cell at bottom; for simplicity, cell surfaces are not shown.
doi:10.1371/journal.pbio.1001149.g007
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Experiments involving mice were approved by the institutional
animal care and use committee.
Peptides
Peptides were synthesized using fluoronyl-methoxycarbonyl
chemistry, cleaved, and the side chain deprotected with triflour-
oacetic acid. Peptides were .95% pure by high-pressure liquid
chromatography; molecular weight was verified by MALDI-TOF
mass spectrometry. Peptides were abutted with D-Ala at both
termini for greater protease resistance in biological assays and with
Cys for SPR. Scrambled sequences were obtained using a true
random number generator (http://www.random.org/).
Soluble CD28, PD-1, and B7-2
CD28, PD-1, and B7-2 expressed in mouse myeloma NS0 cells
(R&D Systems) comprise the extracellular 19–152, 24–167, and
20–239 amino acid domain, respectively, of the mature human
ligands fused to C-terminal human IgG1 Fc and are homodimers,
disulfide-linked in the Fc domain. Soluble ligands were .95%
pure as judged by SDS-PAGE.
Antibodies
Mouse c1 anti-SEB mAb (MB2B33, Toxin Technology),
horseradish peroxidase-conjugated goat anti-mouse IgG (KPL);
mouse IgG1 anti-human CD28 mAb (MAB342, clone 37407),
mouse IgG1 anti-human CD3 epsilon mAb (clone UCHT1),
mouse IgG1 anti-human B7-1/CD80 mAb (clone 37710) and
anti-human B7-2/CD86 mAb (clone 37301), goat IgG anti-human
CD28 polyclonal Ab (AF-342-PB) and goat IgG anti-human B7-
2/CD86 polyclonal Ab (AF-141-NF), from R&D Systems. Binding
of aCD28 to immobilized CD28-Fc and p12B was assayed in
enzyme-linked immunosorbent assays using corresponding alka-
line phosphatase-coupled aIgG (Jackson Laboratories).
Induction of Cytokine Gene Expression
Human PBMC were separated on Ficoll Paque (Amersham),
washed twice with 50 ml of RPMI 1640 medium, resuspended at
4610
6 cells/ml, and cultured in this medium supplemented with
2% fetal calf serum, 2 mM glutamine, 10 mM MEM nonspecific
amino acids, 100 mM Na-pyruvate, 10 mM Hepes pH 7.2,
5610
25 M 2-mercaptoethanol, 100 U/ml penicillin, 100 mg/ml
streptomycin, and 5 mgm l
21 nystatin. SEB (Lot 1430, Department
of Toxinology, U.S. Army Medical Research Institute of Infectious
Diseases), SEA, and TSST-1 (Sigma) were added to 100 ng/ml.
Secreted cytokines, quantitated in triplicate with Quantikine ELISA
kits (R&D Systems), are presented as means 6 SEM.
Ribonuclease Protection Analysis
Total RNA was extracted from aliquots of 3610
7 PBMC with
Trizol reagent (Invitrogen) and hybridized for 18 h at 42uC with
genomic antisense RNA probes transcribed with a-[
32P]UTP from
DNA inserted into pBS (Promega). The 600-nt IL2 probe, a T7
transcript, is complementary to IL2 exon 3 and part of intron 3;
117 nt of this RNA are protected by IL2 mRNA [15]. The 274-nt
IFN-c probe, a T3 transcript, is complementary to IFN-c exon 3
and part of intron 3; 183 nt of this RNA are protected by IFN-c
mRNA [15,33]. The 570-nt TNF-a probe, a T3 transcript, is
complementary to parts of TNF-a intron 3 and exon 4; 220 nt of
this RNA are protected by TNF-a mRNA. Antisense RNA probes
for 18S rRNA and b-actin mRNA protect 90 and 245 nt,
respectively.
Recombinant Superantigens
Chromosomal DNA from S. aureus COL and from an SEA-
producing strain was used to clone wt SEB and SEA genes into
pHTT7K [34] and express them in E. coli as mature proteins with
an N-terminal His6-tag. PCR primers 59-AGCTTGTACGT-
CAAAAGATAATAAAT-39 and 59-AATGCGAAAAAGGT-
GACTGCTCAAG-39 were used to create tk2 SEB. Inserts were
verified by DNA sequencing. Total protein was loaded onto a
HisNBind column (Novagen) and eluted stepwise with imidazole.
Recombinant proteins recovered after dialysis were .98% pure
on SDS-PAGE and .98% homogeneous as monomers upon
analytical gel filtration through a 1630 cm Superdex 75 column
calibrated with molecular weight standards (GE Healthcare-
Amersham Pharmacia) from which proteins were eluted at a flow
rate of 1 ml/min. In PBMC, wt SEB and SEA induced IL2, IFN-c,
TNF-a, and IL10 at 1 ng/ml, attesting to full activity; wt SEB was
lethal to mice in the same concentration range as natural SEB.
Binding of SEB to Cell-Surface CD28
A vector expressing CD28-GFP fusion protein was generated
from CD28 cDNA vector template [35] using KOD polyme-
rase (Novagen) with phosphorylated PCR primers 59-CTCA-
GATCTCGCCACCATGCTCAGGCTGCTCTTGGCTCT and
59-CTCGGATCCGGAGCGATAGGCTGCGAAGTC, deleting
the CD28 termination codon. The PCR product was inserted into
pEGFP-N3 DNA (Clontech) that had been digested with BamH1
and BglII. CD28-transfected cells were incubated successively for
30 min each with wt SEB labeled with Alexa Fluor 633 (Molecular
Probes), goat polyclonal aCD28 Ab (AF-342-PB, R&D Systems),
and Cy2-labeled donkey anti-goat IgG (Jackson Laboratories),
washing after each step.
Far-Western Analysis
wt SEB (28.4 kD), egg white lysozyme (14.3 kD; Sigma), or goat
polyclonal aCD28 (R&D Systems) were incubated for 5 min at
95uC and separated in duplicate by 12% SDS-PAGE. One gel was
stained with Coomassie blue and the other transferred to a
Nitrocellulose Transfer Membrane (Whatman, 0.2 mm) in a Semi
Dry Transfer instrument (Schleicher & Schuell). The membrane
was blocked with 5% skim milk before incubation for 1 h with
0.5 mg/ml horseradish peroxidase-conjugated CD28-Fc (R&D
Systems). Binding of CD28-Fc was detected using ECL-plus
(Pharmacia).
Phage Display
For epitope mapping, the PhD-12 combinatorial phage display
library in M13KE (New England Biolabs) was panned on
immobilized aCD28 mAb (MAB342) following instructions of
the manufacturer; displacement was with 100 mg/ml CD28-Fc.
Phages from the fourth panning were immobilized on nitrocellu-
lose membranes. Binding of aCD28 was detected with horseradish
peroxidase-linked anti-mouse IgG (Jackson Laboratories) using
ECL-plus. Sequences of 19 distinct inserts were aligned with
CD28, without gaps. For CD28 affinity selection, the same library
was panned on immobilized CD28-Fc; bound phages were
displaced with 100 mg/ml SEB (Lot 1430). To screen for binding,
phages were immobilized and incubated with 0.5 mg/ml horse-
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panning, .10% of selected phages tightly bound CD28-Fc.
Surface Plasmon Resonance Spectroscopy
Proteins and peptides were diluted to 10–200 mg/ml in 10 mM
Na acetate pH 4.0 and immobilized on a CM5 sensorchip using
amine coupling kit and amine-thiol coupling kit (BIAcore),
respectively; amounts immobilized were 500–1,000 RU. Analytes
were injected at 20 ml/min in 25 mM HEPES pH 7.4, 150 mM
NaCl, 3.4 mM EDTA, and 0.005% surfactant P20 under
conditions showing no mass transport limitation. Regeneration
was with 50 mM phosphoric acid. Kinetic analyses were
performed at 25uC in a BIAcore 3000 instrument, deducting
the control flow cell signal from the binding signal. Analyte
curves were run in duplicate; representative results are shown.
BIAevaluation 3.1 software was used to determine KD in the
linear ligand concentration range (1:1 Langmuir binding). To
determine KD for the SEB/CD28-Fc complex from data in
Figure 3C, CD28-Fc bound to immobilized p12C in the presence
of increasing concentrations of SEB was quantitated relative to
the dose response curve generated for binding of CD28-Fc to
p12C in the absence of SEB. Standard error as percent of ka and
kd and x
2 values well below 10 show the quality of fit between
calculated and observed binding values and attest to the purity of
the ligands examined. Fitting residuals were within the range of
62, validating the goodness of fit. CD28-Fc was titrated in
BIAcore binding assays for the ability to bind to its cognate
immobilized mAb. CD28-Fc was also titrated for its ability to
bind to immobilized sB7-2. Human IgG (Jackson Laboratories),
ribonuclease A, and His10-tagged ubiquitin (R&D Systems)
served as controls.
Mouse Lethality Assay
Female BALB/c mice (10–12 wk; Harlan) were challenged by
intraperitoneal injection of SEB and 20 mg D-galactosamine to
sensitize the animals to superantigens [15]. Antagonist peptides
were injected intraperitoneally 30 min before challenge. Controls
without SEB received peptide 30 min before injection of D-
galactosamine. Survival was monitored. Viability remained
constant beyond 72 h for as long as monitored, 2 wk.
Statistical Analysis
Survival curves were analyzed using the Kaplan-Meier method,
with the Log-Rank test for comparisons.
Structure Models
Cartoon models of protein structure were created in PyMol
(www.pymol.org).
Supporting Information
Figure S1 Induction of a Th1 cytokine response by SEB relies
on B7-2/CD28 signaling. (A) aB7-2 inhibits SEB-induced
expression of IL2 and IFN-c genes but not of IL4 and IL10.
PBMC were induced with SEB alone or with 100 ng/ml aB7-1 or
aB7-2 monoclonal antibody. Graphs show IL2 and IFN-c mRNA
determined by quantitative dot-blot hybridization (vertical rows in
autoradiogram below each graph show 8-h values) [15] and
cytokines secreted into culture medium (data are shown as means
6 SEM (n=3)). (B) CD28-Fc inhibits SEB-mediated induction of
IL2 and IFN-c mRNA but not of IL10. PBMC were induced with
SEB, 1 mg/ml CD28-Fc, or both. IL2 and IFN-c mRNA was
determined by RNase protection analysis; b-actin mRNA indicates
equal loading of RNA. IL10 level is shown (data are shown as
means 6 SEM (n=3)).
(PDF)
Figure S2 Binding of CD28 to SEB and to p12C is specific. (A)
Purity of CD28-Fc (1 mg) was assessed by 12% SDS-PAGE and
staining with Coomassie blue. M, molecular weight marker. (B)
Representative SPR responses for binding of human IgG in
concentrations ranging from 0.25 mM in 2-fold increments to
immobilized SEB (Lot 1430). (C, D) Representative SPR responses
for binding of human IgG (C) and His10-tagged ubiquitin (D) in
concentrations ranging from 0.125 mM in 2-fold increments to
immobilized p12C. (E) Representative SPR responses for binding
of B7-2-Fc in 2-fold increments from 0.03 mM to CD28-Fc
immobilized as in Figure 5B.
(PDF)
Figure S3 Mimetic peptide p12C is an active SEB antagonist.
PBMC were induced with SEB alone or with 100 ng/ml p12A or
p12C. IL2 and IFN-c mRNA were quantitated by RNase
protection analysis (autoradiograms).
(PDF)
Figure S4 Antagonist peptides in the CD28 dimer interface. A
still of Movie S1. In CD28 extracellular domain (1yjd.pdb), location
is shown of homodimer interface peptides p1TA (HVK resolved in
1yjd.pdb is red), p2TA (green), p3TA (pink), p4TA (grey), and p5TA
(SNGTII is blue) (see Figure 4A); MYPPPY is yellow.
(PDF)
Figure S5 SEB induces a transient change in surface accessibility
of CD28 epitope HVKGKHLCP. CD4 cells were enriched to
90% from PBMC by use of RosetteSep (Stem Cell Technologies),
incubated at a density of 4610
6 cells/ml and before addition of
SEB (0 h), or at times indicated, washed, and stained with aCD28
mAb (secondary Ab: Cy-2, green) or goat polyclonal CD28 Ab
(secondary Ab: Cy-3, red). Confocal fluorescence microscopy is
shown. Merge, double staining with both antibodies.
(PDF)
Movie S1 Antagonist peptides in the CD28 dimer interface. In
CD28 extracellular domain (1yjd.pdb), location is shown of
homodimer interface peptides p1TA (HVK resolved in 1yjd.pdb
is red), p2TA (green), p3TA (pink), p4TA (grey), and p5TA
(SNGTII is blue) (see Figure 4A); MYPPPY is yellow.
(MOV)
Table S1 Kinetic parameters of surface plasmon resonance
analysis in Figure 5.
(PDF)
Table S2 Kinetic parameters of surface plasmon resonance
analysis in Figure 6.
(PDF)
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